<DOC>
	<DOCNO>NCT02652598</DOCNO>
	<brief_summary>The experimental design open-label two-week trial tolcapone evaluate clinical domain affect tolcapone treatment identify `` responder '' tolcapone treatment two subject group ( BI NCD )</brief_summary>
	<brief_title>Evaluate Effects Tolcapone Cognitive Behavioral Dysfunction Patients With BI NCD</brief_title>
	<detailed_description>Each patient receive two-week specify dosing amount tolcapone ( 100mg TID Day 1 ; 200mg TID Days 2-14 ) . The patient instruct take study drug three time daily . Tolcapone taper Day 14 avoid potential withdrawal reaction . Clinical Instruments patient : - Question bank large patient-reported outcome measure initiative use administer used computerized-adaptive test ( CATs ) . These include TBI-QoL patient TBI question bank patient-reported outcome measure information system ( PROMIS ) neurology quality life measurement initiative ( Neuro-QoL ) . Patients answer question related mobility , fatigue , pain interference , positive affect well-being , depression , anxiety , anger irritability , emotional behavioral dyscontrol . - Clinical Global Impressions Scale - Geriatric Depression Scale-15 - State-Trait Anxiety Inventory - Hopkins Adult Reading Test - Frontal Systems Behavior Scale - Montreal Cognitive Assessment - Trails A &amp; B - Modified Wisconsin Card Sorting Test - NIH Toolbox - Perceptual Comparison Test - Brief Test Attention - Hopkins Verbal Learning Test - Brief Visuospatial Memory Test - Calibrated Ideational Fluency Assessment - Profile Mood States - Digit Span Clinical Instruments Informants : - Neuropsychiatry Inventory - Apathy evaluation scale - Overt aggression scale - Frontal Systems Behavior Scale Laboratory Measures : - Blood sample genotyping - Blood sample assess COMT activity . - Blood sample laboratory profile include CBC , CMP , TSH , Hepatitis Panel ( B C ) , RPR - A urine analysis , urine drug screen , urine pregnancy test - In addition NCD patient : blood sample test include Serum Calcium , B12 , ESR , C-reactive protein</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<criteria>TBI ABI Patients Inclusion Criteria Age 1870 Diagnosis mild , moderate , severe TBI , history ABI classification make base parameter time index event acquire brain injury . Index event result Traumatic Acquired Head Injury occur &gt; 12 month prior trial initiation A current former patient clinic Sheppard Pratt Neuropsychiatry Program another Sheppard Pratt outpatient clinic medical documentation TBI ABI Proficient English language Available come Sheppard Pratt Towson baseline evaluation test duration protocol Stable neurological psychiatric symptomatology 2 month prior trial initiation determine refer Sheppard Pratt physician . Stable medication dose regimen 2 month NCD Patients Inclusion Criteria Age 6075 NCD diagnose Sheppard Pratt physician , per DSM5 No abnormality serum test rule cause cognitive impairment : TSH , B12 , CBC , Chemistry screen , RPR . Recent structural neuroimaging ( within 1 year since time onset cognitive complaint ) noncontrast head CT MRIto rule gross lesion inconsistent diagnosis MCI ( e.g . subdural hematoma , normal pressure hydrocephalus , demyelinate lesion , infarct , mass lesion ) Proficient English language A current former patient clinic Sheppard Pratt Neuropsychiatry Program another Sheppard Pratt outpatient clinic medical documentation NCD Available come Sheppard Pratt Towson baseline evaluation test duration protocol Stable neurological psychiatric symptomatology 2 month prior trial initiation determine impression refer Sheppard Pratt physician . Stable medication dose regimen 2 month Exclusion Criteria All Patients : History , active , liver disease abnormal liver function testsif patient currently elevate Alanine Transaminase ( ALT ) Aspartate Transaminase ( AST ) level exceed 2 time upper limit normal [ Normal Reference Ranges ALT ( Male : 440 IU/L , Female : 440 IU/L ) , AST ( Male : 431 IU/L , Female : 437 IU/L ) ratio AST : ALT exceed 2:1 Active alcohol use disorder , define DSM5 , severity mild , moderate , severe History , active , cardiovascular disease define : coronary heart disease , manifest myocardial infarction , angina pectoris , heart failure Uncontrolled hypoor hypertension base Joint National Committee criterion ( JNC7 ) Hypotension : Systolic &lt; 90mmHg diastolic &lt; 60mmHg Hypertension : Systolic &gt; 140mmHg diastolic &gt; 90 mmHg ) History extrapyramidal symptom ( e.g . tardive dyskinesia , neuroleptic malignant syndrome , QT prolongation ) firstgeneration antipsychotic Active illicit substance use , result substance use disorder define DSM5 , severity mild , moderate , severe Patient currently take tolcapone follow medication interact tolcapone result adverse event : another COMT inhibitor , benserazide , αmethyldopa , dobutamine , apomorphine , isoproterenol , clozapine , MAO inhibitor Known allergy serious adverse reaction tolcapone Participated investigational drug trial past 30 day . Pregnant plan become pregnant study period Breastfeeding planning breastfeed study period . Other Exclusion Criteria TBI Patients • Presence premorbid/preTBI cognitive impairment behavioral dysfunction , per informant medical documentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>